• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medical device company M&A: Masimo no longer on the hunt for big deals

Medical device company M&A: Masimo no longer on the hunt for big deals

September 20, 2012 By MassDevice staff

Masimo logo

Masimo (NSDQ:MASI) CEO Joe Kiani told investors today that the medical device company isn’t weighing any more big moves on the mergers & acquisitions front, a pivot from comments he made earlier this year.

Kiani, speaking at Irvine, Calif.-based Masimo’s investor day in New York City, said that although he was "bullish" earlier in the year that the company would make some moves on the acquisition front, he has since pulled back from that position.

"Nothing is in the pipeline of any magnitude," Kiani said.

Sign up to get our free newsletters delivered straight to your inbox

Masimo will instead look to either increase dividend payments to shareholders or execute a share buyback, he said. Although he didn’t specify any plans for cash on hand of about $122 million as of the end of the 1st quarter, Kiani said Masimo’s next move could be tied to whether or not President Barack Obama is re-elected in November, which could signal an increase in the capital gains tax.

Kiani recently told MassDevice.com that he often has to balance the needs of investors with the long-term growth of the company.

"I think the investors typically have 1 measurement, and that is the stock price. Although as a native shareholder, the stock price is important to me, I don’t look at it daily or monthly. I look at it as, ‘What can our management team do so that I can assure a solid stock price whenever it is – 5 years from now?’" he told us.
"I’m trying to do what we can do to make Masimo fundamentally strong – make products that improve patient care, because that will be valuable and we’ll be rewarded for it. The investors have a shorter outlook, unfortunately. And I think that’s one of the big problems of public companies starting to look quarterly instead of what they can really control long-term. So we feel pressure and we’re sensitive to it, but I still can’t run the company based on that. I’ve got to run the company based on what we think is right to do."

Masimo hasn’t been silent on the market though. The company made a $30 million acquistion of capnometery solutions developer Phasein in August.

Filed Under: Mergers & Acquisitions, News Well, Patient Monitoring Tagged With: Masimo

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy